ReWalk Personal 6.0 im Hilfsmittelverzeichnis aufgenommen

Die Listung im Hilfsmittelverzeichnis ermöglicht allen geeigneten Personen die Kostenübernahme für ein ReWalk Personal Exoskelett durch die gesetzlichen Krankenversicherungen, welche 90% der deutschen Bevölkerung versichern

MARLBOROUGH, MA / BERLIN, DEUTSCHLAND// –12. Juni 2018 — ReWalk Robotics, Ltd. (Nasdaq: RWLK) („ReWalk Robotics“ oder „das Unternehmen“) gab heute bekannt, dass das ReWalk Personal Exoskelett vom GKV-Spitzenverband offiziell in das Hilfsmittelverzeichnis aufgenommen wurde.

ReWalk ist das erste und einzige Exoskelett für Rückenmarksverletze, welches im Hilfsmittelverzeichnis (gemäß §139 SGB V) gelistet ist. Dadurch ist das System offiziell als Hilfsmittel (gemäß §33 SGB V) in Deutschland anerkannt.

Das Hilfsmittelverzeichnis beinhaltet umfassende Informationen zur Leistungspflicht der Krankenkassen sowie über die Art und Qualität der am Markt erhältlichen Produkte.

Das Bundesministerium der Justiz und für Verbraucherschutz gab diese Woche im Bundesanzeiger die Aufnahme des ReWalk Personal in das Hilfsmittelverzeichnis bekannt, welches vom GKV-Spitzenverband erstellt und fortlaufend aktualisiert wird.

Dem ReWalk Personal Exoskelett wurde die Hilfsmittelnummer 23.29.01.2001 mit folgender Indikation zugewiesen: „Beidseitige Lähmung der Hüft-, Oberschenkel- und Unterschenkelmuskulatur (Querschnittslähmung mit Paraplegie) und Verlust der Gehfähigkeit.“

„Der GKV-Spitzenverband setzt mit der Veröffentlichung der Hilfsmittelnummer einen Meilenstein in der Versorgung von Rückenmarksverletzten mit Exoskeletten“, sagte Larry Jasinski, CEO von ReWalk Robotics. „Das deutsche Gesundheitssystem zeichnet sich dadurch als weltweit führend mit einer innovativen Gesundheitspolitik für seine Bürger aus.“

Ab sofort kann die Kostenübernahme für das ReWalk Personal bei den gesetzlichen Krankenkassen mit der oben genannten Hilfsmittelnummer für Versicherte beantragt werden.

About ReWalk Robotics Ltd.

ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury. The company’s mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany. For more information on the ReWalk systems, please visit www.rewalk.com/de.

ReWalk® is a registered trademark of ReWalk Robotics Ltd. in Israel.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding ReWalk’s future performance and, in some cases, may be identified by words like “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “should,” “would,” “seek” and similar terms or phrases. The forward-looking statements contained in this press release are based on management’s current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk’s control. Important factors that could cause ReWalk’s actual results to differ materially from those indicated in the forward-looking statements include, among others: ReWalk’s expectations regarding future growth, including its ability to increase sales in its existing geographic markets, and to expand to new markets and achieve its planned expense reductions; the conclusion of ReWalk’s management and the previous opinion of ReWalk’s auditors in that there are substantial doubts as to ReWalk’s ability to continue as a going concern; ReWalk’s ability to maintain and grow its reputation and the market acceptance of its products; ReWalk’s ability to achieve reimbursement from third-party payors for its products; ReWalk’s expectations as to its clinical research program and clinical results; ReWalk’s expectations as to the results of, and the Food and Drug Administration’s potential regulatory developments with respect to, ReWalk’s mandatory post-market 522 surveillance study; the outcome of ongoing shareholder class action litigation relating to ReWalk’s initial public offering; ReWalk’s ability to repay its secured indebtedness; ReWalk’s ability to improve its products and develop new products; ReWalk’s ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; ReWalk’s ability to gain and maintain regulatory approvals; ReWalk’s ability to secure capital from its equity and debt financings in light of limitations under its Form S-3, the price range of its ordinary shares and conditions in the financial markets, and the risk that such financings may dilute ReWalk’s shareholders or restrict its business; ReWalk’s ability to use effectively the proceeds of offerings of securities; ReWalk’s ability to maintain relationships with existing customers and develop relationships with new customers; the impact of the market price of ReWalk’s ordinary shares on the determination of whether ReWalk is a passive foreign investment company; ReWalk’s ability to maintain compliance with the continued listing requirements of the NASDAQ Capital Market; ReWalk’s compliance with medical device reporting regulations to report adverse events involving its products and the potential impact of such adverse events on ReWalk’s ability to market and sell its products; the risk of substantial dilution resulting from the issuance to Timwell; the significant voting power and de facto voting control Timwell may acquire; the risk that the remaining Timwell issuances will fail to close and the China joint venture will not form; and other factors discussed under the heading “Risk Factors” in ReWalk’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 filed with the U.S. Securities and Exchange Commission (the “SEC”) and other documents subsequently filed with or furnished to the SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause ReWalk’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.